Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 1 4Phase 2 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Leiomyoma 4Endometriosis 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × vilaprisan × Clear all
NCT03342859 2021-01-06

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Bayer

Phase 1 Terminated
10 enrolled

Leiomyoma

NCT03411980 2019-12-03

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Bayer

Phase 1 Completed
26 enrolled

Endometriosis, Leiomyoma

NCT03092999 2017-08-18

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

Bayer

Phase 1 Completed
36 enrolled

Leiomyoma

NCT01816815 2014-04-21

Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670

Bayer

Phase 1 Completed
73 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡